In summary, this study reports the promising association of individual immunotherapy panel markers CD274, PDCD1LG2, CD8A, IRF1 and a combined L1/L2 score (CD274 & PDCD1LG2) with improved immunotherapy outcome in metastatic melanoma. Here, CD8A is linked to metastatic melanoma.